Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors

Anticancer Research

Volumn 26, Issue 1 B, 2006, Pages 703-707

  Forrer, Flavio ^a   Waldherr, Christian ^a   Maecke, Helmut R ^a   Mueller Brand, Jan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

90Y DOTATOC; Neuroendocrine tumor; Quality of life; Somatostatin; Targeted radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] Y 90; INDIUM 111; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; CANCER STAGING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; ISOTOPE LABELING; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PANCYTOPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOISOTOPE THERAPY; SYMPTOMATOLOGY; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR SCINTISCANNING; VOMITING;

HUMANS; INTESTINAL NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; OCTREOTIDE; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 32144463528     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jensen RT and Norton JA: Carcinoid tumors and the carcinoid syndrome. In: DeVita VT, Heilman S and Rosenburg SA (eds.). Cancer: Principles and Practice of Oncology, 5th ed. Cambridge, MA: Blackwell Scientific Publications, pp. 1706, 1996.
2. Reubi JC, Waser B, Schaer JC et al: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28: 836-846, 2001.
3. Higgins GA, Recant L and Fischman AB: The glucagonoma syndrome: surgically curable diabetes. Am J Surg 137: 142-148, 1979.
4. Prinz RA, Dorsch TR and Lawrence AM: Clinical aspects of glucagon-producing islet cell tumors. Am J Gastroenterol 76: 125-131, 1981.
5. Schnirer II, Yao JC and Ajani JA: Carcinoid - a comprehensive review. Acta Oncol 42: 672-692, 2003.
6. Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1: 727-740, 1983.
7. Oberg K, Norheim I, Lundqvist G et al: Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin - alone or in combination with 5-FU. Acta Oncol 26: 429-432, 1987.
8. Engstrom PF, Lavin PT and Moertel CG: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2: 1255-1259, 1984.
9. Moertel CG and Hanley JA: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2: 327-334, 1979.
10. Arnold R, Trautmann ME, Creutzfeldt W et al: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38: 430-438, 1996.
11. Creutzfeldt W, Bartsch HH, Jacubaschke U et al: Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. Acta Oncol 30: 529-535, 1991.
12. Valimaki M, Jarvinen H, Salmela P et al: Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 67: 547-549, 1991.
13. Oberg K, Eriksson B and Janson ET: The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Ann NY Acad Sci 733: 471-478, 1994.
14. Otte A, Jermann E, Behe M et al: DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24: 792-795, 1997.
15. Otte A, Mueller-Brand J, Dellas S et al: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351: 417-418, 1998.
16. Waldherr C, Schumacher T, Pless M et al: Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 22: 673-678, 2001.
17. de Jong M, Kwekkeboom D, Valkema R et al: Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imag 30: 463-469, 2003.
18. 3]octreotate. Eur J Nucl Med Mol Imag 30: 417-422, 2003.
19. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imag 30: 207-216, 2003.
20. 90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imag 31: 1038-1046, 2004.
21. Waldherr C, Pless M, Maecke HR et al: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43: 610-616, 2002.
22. 3]octreotate. J Clin Oncol 22: 2724-2729, 2004.
23. Forrer F, Uusijarvi H, Waldherr C et al: A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imag 31: 1257-1262, 2004.
24. Otte A, Herrmann R, Heppeler A et al: Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26: 1439-1447, 1999.
25. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12: 941-945, 2001.
26. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 24: 368-371, 1997.
27. Bernhardt P, Forssell-Aronsson E, Jacobsson L et al: Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 40: 602-608, 2001.
28. 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm 18: 761-768, 2003.
29. 3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 92: 628-633, 2001.
30. Suzuki Y, Hasegawa M, Hayakawa K et al: In vivo study of radiosensitizing effect of hypoxic cell radiosensitizer PR-350 on a human small cell lung cancer. Anticancer Res 19: 3993-4000, 1999.
31. Gridelli C, Curcio C, Iaffaioli RV et al: Carboplatin + epirubicin + VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study. Anticancer Res 21: 4179-4183, 2001.